Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. The phase 3 study linked the oral GLP-1 drug orforglipron to similar reductions in blood glucose and body ...

After mass layoffs, the FDA has started missing certain deadlines, pushing one biopharma to delay a phase 3 trial and consider other paths to market, The Wall Street Journal reports. Women’s ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, establishing leadership in obesity treatment. Orforglipron offers advantages ...

(RTTNews) - Eli Lilly and Company (LLY) Thursday reported topline data from Phase 3 ACHIEVE-1 study of orforglipron in adults with type 2 diabetes. The study met its primary goal. ACHIEVE-1 is the ...

Mark Huffman has been a consumer news reporter for ConsumerAffairs since 2004. He covers real estate, gas prices and the economy and has reported extensively on negative-option sales. He was ...

Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. The OCEANIC trial ...

Data from the two phase 3 studies also showed that clinical decline was reduced in participants who had plasma p-tau181 reduction at 78 weeks, which Haeberlein said was a "meaningful" finding.

Lilly is running Phase 3 studies on orforglipron for the treatment of type 2 diabetes and for weight management in adults with obesity or overweight with at least one weight-related medical problem.

Eli Lil­ly re­port­ed the first Phase 3 da­ta for its oral GLP-1 or­for­glipron Thurs­day morn­ing, say­ing the drug suc­ceed­ed in a type 2 di­a­betes tri­al … ...

Following Committee of the Whole recommendations, the Hopkinsville City Council will consider the renaming of a local park, a ward map amendment, and a transportation grant for Phase 3 of the Greenway ...

The phase 3 KEEPsAKE 2 trial investigated the efficacy and safety of risankizumab versus placebo in patients with active PsA who had previous inadequate response or intolerance to ≤2 biological ...